Vaxart Announces Positive Phase 1 Norovirus Vaccine Results

An update from Vaxart ( (VXRT) ) is now available.

On June 11, 2025, Vaxart announced positive results from its Phase 1 clinical trial for its second-generation oral pill norovirus vaccine constructs. The trial demonstrated that the new constructs significantly increased antibody responses compared to the first-generation constructs, with a 141% and 94% increase in GI.1 and GII.4 norovirus blocking antibodies, respectively. The vaccines were well-tolerated with no serious adverse events reported. These results suggest the potential for improved protection against norovirus, a virus with no currently approved vaccine that causes millions of infections globally, leading to significant economic burdens. Vaxart plans to incorporate these findings into discussions with potential partners and aims to advance to a Phase 2b study, potentially starting in the latter half of 2025.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall stock score is primarily driven by financial challenges, including ongoing losses and negative cash flows. While recent clinical trial progress and strategic moves offer potential, these are tempered by delisting risks and valuation concerns. Technical indicators further suggest bearish momentum.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered as pills, eliminating the need for refrigeration and reducing the risk of needle-stick injuries. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).

Average Trading Volume: 2,055,123

Technical Sentiment Signal: Sell

Current Market Cap: $89.7M

See more data about VXRT stock on TipRanks’ Stock Analysis page.